Sorrento Therapeutics, Inc. Share Price Deutsche Boerse AG
Equities
8STN
US83587F2020
Biotechnology & Medical Research
Sales 2021 | 5.29Cr 4.85Cr 441.73Cr | Sales 2022 | 6.28Cr 5.77Cr 524.69Cr | Capitalization | 41Cr 38Cr 3.43TCr |
---|---|---|---|---|---|
Net income 2021 | -43Cr -39Cr -3.57TCr | Net income 2022 | -57Cr -53Cr -4.78TCr | EV / Sales 2021 | 29.1 x |
Net Debt 2021 | 11Cr 10Cr 924.27Cr | Net Debt 2022 | 8.45Cr 7.76Cr 705.77Cr | EV / Sales 2022 | 7.89 x |
P/E ratio 2021 |
-3.2
x | P/E ratio 2022 |
-0.65
x | Employees | 949 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 97.77% |
Managers | Title | Age | Since |
---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 59 | 01/89/01 |
Shawn Sahebi
COO | Chief Operating Officer | - | - |
Mike A. Royal
CTO | Chief Tech/Sci/R&D Officer | 70 | 03/14/03 |
Members of the board | Title | Age | Since |
---|---|---|---|
Kim D. Janda
BRD | Director/Board Member | 67 | 01/12/01 |
David Lemus
BRD | Director/Board Member | 61 | 01/17/01 |
Jaisim Shah
BRD | Director/Board Member | 63 | 11/13/11 |
1st Jan change | Capi. | |
---|---|---|
+20.17% | 13TCr | |
+24.67% | 12TCr | |
+25.44% | 2.77TCr | |
-17.74% | 2.03TCr | |
-15.17% | 1.68TCr | |
-15.21% | 1.56TCr | |
+11.91% | 1.48TCr | |
-47.10% | 1.46TCr | |
+54.50% | 1.44TCr |